Regulatory Show all
July 23 | 2019

2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial

Read more
July 23 | 2019

2cureX meddelar att patienter framgångsrikt inkluderats i pankreascancerstudie med IndiTreat®

Read more
June 27 | 2019

Last day of trading in BTA 1 in 2cureX AB

Read more
June 27 | 2019

Sista dag för handel med BTA 1 i 2cureX AB

Read more
June 20 | 2019

2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer

Read more
June 20 | 2019

2cureX utser Dr. Henrik Harling till Chief Medical Officer

Read more
May 28 | 2019

Kommuniké från årsstämma i 2cureX AB (publ)

Read more
May 28 | 2019

Communique from the Annual General Meeting in 2cureX AB (publ)

Read more
May 28 | 2019

Kraftigt övertecknad företrädesemission i 2cureX AB

Read more
May 28 | 2019

Significantly oversubscribed rights issue in 2cureX AB

Read more
May 9 | 2019

CORRECTION: 2cureX publishes interim report for the first quarter of 2019

Read more
May 9 | 2019

Idag inleds teckningstiden i 2cureX företrädesemission

Read more
May 9 | 2019

Today, the subscription period starts in 2cureX’s rights issue

Read more
May 8 | 2019

2cureX offentliggör memorandum inför företrädesemissionen

Read more
May 8 | 2019

2cureX publishes memorandum ahead of the rights issue

Read more
May 8 | 2019

2cureX publishes interim report for the first quarter of 2019

Read more
May 8 | 2019

2cureX offentliggör delårsrapport för det första kvartalet 2019

Read more
May 7 | 2019

2cureX publishes the annual report for the fiscal year 2018

Read more